OS Therapies Revenue and Competitors

Location

Total Funding

Industry

Estimated Revenue & Valuation

Name	Title	Email/Phone

Competitor Name	Revenue	Number of Employees	Employee Growth	Total Funding	Valuation
#1 Dermavant Scien...	$99.4M	458	40%	N/A	N/A
#2 Metrum Research...	$20.6M	133	22%	N/A	N/A
#3 Clovis Oncology	$156.1M	146	-70%	$145M	N/A
#4 ArcherDX	$3.5M	45	-25%	$150M	N/A
#5 Inscripta	$1.6M	21	0%	$459.5M	N/A
#6 Cerapedics	$67.3M	310	16%	$180.7M	N/A
#7 Stone Clinical ...	$8.5M	55	-2%	N/A	N/A
#8 Apellis Pharmac...	$256.3M	1025	9%	$168.5M	N/A
#9 CreoSalus	$2.8M	18	-33%	N/A	N/A
#10 MSBiotec	$9.1M	59	-9%	N/A	N/A

keywords:N/A

$7M

Total Funding

Number of Employees

$852.5k

Revenue (est)

57%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Again, OS is a secondary endpoint that is not a requisite but it would support approval. This is where the plot thickens. Specifically, the FDA...

TG Therapeutics made the decision to voluntarily pull the biologics ... which highlighted a growing imbalance in overall survival (OS).

Although immune checkpoint inhibition is used to treat many cancers, for most cancer types fewer than 50% of patients respond to therapy.

Company Name	Revenue	Number of Employees	Employee Growth	Total Funding
#1 W-Systems	$1M	11	0%	N/A
#2 Qordoba	$0.8M	11	0%	$21.5M
#3 Adjust Your Set	$1.7M	11	-45%	N/A
#4 INSynQ BV	$1M	11	0%	N/A
#5 IMH Groupe (IMH...	$1M	11	-8%	N/A